EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with COPD

Dinesh Saralaya, M. Nubli Mustapa, João Ferreira, Janwillem W.H. Kocks, Wayne Brailsford, Sanna Rosengren, Enti Spata, Maria G. Belvisi, Jacob Leander, Camille Riff, Giovanna De Palo, Daniel Windgassen, James D. Chalmers, Richard E.K. Russell, John R. Hurst, Adam Śmiałowski, Rod Hughes

European Respiratory Journal · 2026-11 · 68 (5) · 2502567

DOI: 10.1183/13993003.02567-2025 ↗
AbstractBibliografische Angaben

Abstract

Background Neutrophilic inflammation is a common feature of COPD. Mitiperstat, an inhibitor of myeloperoxidase expressed in neutrophils, may have potential as a COPD treatment. Methods This phase 2a, randomised, placebo-controlled, double-blind, parallel-arm, event-driven trial evaluated the efficacy and safety of mitiperstat 5 mg once daily for up to 24 weeks (CRESCENDO; ClinicalTrials.gov : NCT05492877 ). Adults (40–80 years) with moderate-to-severe COPD, at high risk of exacerbation and receiving dual or triple inhaled therapy were included. The primary end-point was time to first composite end-point for exacerbations in COPD (COPDCompEx) event. Secondary end-points included time to first moderate-to-severe COPD exacerbation, post-bronchodilator forced expiratory volume in 1 s (post-BD FEV 1 ) change at week 12, respiratory symptoms, disease impact and safety. Results Overall, 381 participants (mean age 66.0 years; 39.6% female) were randomised to mitiperstat (n=189) or placebo (n=192). In total, 125 (66.1%) mitiperstat-treated versus 125 (65.1%) placebo-treated participants experienced COPDCompEx events over 24 weeks. There was no improvement in time to first COPDCompEx event (hazard ratio (HR) 1.07, 90% CI 0.87–1.32; p=0.599) or time to first moderate-to-severe COPD exacerbation (HR 1.23, 90% CI 0.88–1.73) with mitiperstat versus placebo. Improvements in post-BD FEV 1 , respiratory symptoms or disease impact were not seen with mitiperstat. A similar proportion of participants in both groups reported adverse events; seven mitiperstat-treated participants and two placebo-treated participants had pneumonia during the study. Conclusion These results indicate that the risks outweigh the benefits of mitiperstat as a treatment for COPD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →